Daewoong Pharmaceutical's COVID-19 Treatment 'DWRX2003' Selected for Government Project

[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical's 'DWRX200', developed as a treatment for the novel coronavirus infection (COVID-19), has been finally selected as a target project for the government's COVID-19 treatment clinical support program.

On the 1st, Daewoong Pharmaceutical announced, "DWRX2003 is the only synthetic drug among COVID-19 treatments to be finally selected as a government clinical support project." It was explained that the final development potential based on efficacy and safety, as well as the technical value such as a single-dose injectable formulation, were highly evaluated.

Following this selection, Daewoong Pharmaceutical will receive about 5 billion KRW in support for clinical trial costs of DWRX2003 conducted domestically and internationally until September 2021. The company plans to start a multinational Phase 2 clinical trial early next year, secure clinical results, and then pursue conditional approval.

Jeon Seung-ho, CEO of Daewoong Pharmaceutical, said, "With the selection as a target project for this clinical support program, we can accelerate clinical trials underway both domestically and overseas," and added, "We aim to innovate the treatment paradigm that can respond to future COVID Nth wave pandemics and the post-COVID era."